Aegis Therapeutics To Present At The "13th Annual Drug Delivery Summit" In New Brunswick, NJ, September 22-23, 2008
Main Category: ConferencesArticle Date: 24 Aug 2008 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will present a talk entitled: "New Technologies Expanding Practical Clinical Uses of Peptides, Proteins, and Other Macromolecular Therapeutics" at Insight's "13th Annual Drug Delivery Summit." The conference will be held on September 22-23, 2008 at the Hyatt Regency, New Brunswick, NJ. Dr. Edward T. Maggio, President and CEO of Aegis, will present studies on the application of Aegis' Intravail® non-invasive drug delivery technology, and Aegis' ProTek® protein stabilization technology to specific peptide, protein, and small molecule therapeutics.
Information about the conference may be obtained from the following website.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.
Aegis Therapeutics
Visit our conferences section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/118926.php>
APA
http://www.medicalnewstoday.com/releases/118926.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



